A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation

Alex Y. Ge, Abolfazl Arab, Raymond Dai, Albertas Navickas, Lisa Fish, Kristle Garcia, Hosseinali Asgharian, Jackson Goudreau, Sean M. Lee, Kathryn Keenan, Melissa B. Pappalardi, Michael T. McCabe, Laralynne Przybyla, Hani Goodarzi, Luke A. GilbertbioRxiv 2022 · DOI

Abstract

The search for new approaches in cancer therapy requires a mechanistic understanding of cancer vulnerabilities and anti-cancer drug mechanisms of action. Problematically, some effective therapeutics target cancer vulnerabilities that have poorly defined mechanisms of anti-cancer activity. One such drug is decitabine, a frontline therapeutic approved for the treatment of high-risk acute myeloid leukemia (AML). Decitabine is thought to kill cancer cells selectively via inhibition of DNA methyltransferase enzymes, but the genes and mechanisms involved remain unclear. Here, we apply an integrated multiomics and CRISPR functional genomics approach to identify genes and processes associated with response to decitabine in AML cells. Our integrated multiomics approach reveals RNA dynamics are key regulators of DNA hypomethylation induced cell death. Specifically, regulation of RNA decapping, splicing and RNA methylation emerge as important regulators of cellular response to decitabine.

Introduction

Decitabine is a cornerstone of treatment for patients with high-risk Acute Myeloid Leukemia (AML). As a DNA hypomethylating agent (HMA), its primary known function is the inhibition of DNA methyltransferase (DNMT) enzymes, which leads to a global reduction in DNA methylation. However, the specific molecular trajectory from DNA hypomethylation to cancer cell death has remained elusive. This lack of mechanistic clarity hinders the development of predictive biomarkers and the identification of effective combination therapies. This study sought to map the functional landscape of decitabine response to uncover new therapeutic vulnerabilities in AML.

Methodology

To achieve a comprehensive view of the cellular response, researchers utilized an integrated multiomics strategy centered on the HL-60 AML cell line (a TP53-mutant model). The approach combined:

  • Functional Genomics: A genome-scale CRISPR interference (CRISPRi) screen to identify genes whose knockdown modulates sensitivity or resistance to decitabine.
  • Transcriptomics and Stability Analysis: RNA-seq was paired with the REMBRANDTS tool to distinguish between changes in gene transcription and changes in RNA stability.
  • Epitranscriptomics: MeRIP-seq was employed to map $m^6A$ RNA methylation patterns.
  • Translatomics: Ribo-seq assessed changes in translation efficiency.
  • Validation: Findings were validated across a panel of five additional AML cell lines (KG-1, THP-1, OCI-AML2, OCI-AML3, and MOLM-14) and through synergy experiments with the clinical-grade DCPS inhibitor RG3039.

Results and Discussion

The DNA-RNA Methylation Paradox

A central discovery of this research is the "methylation paradox": while decitabine successfully induces DNA hypomethylation, it simultaneously triggers global mRNA hypermethylation ($m^6A$). The authors propose a metabolic redirection model where the inhibition and trapping of DNA methyltransferases increase the available pool of methyl donors (S-adenosylmethionine, or SAM). This surplus is then diverted toward RNA methyltransferases, leading to increased $m^6A$ levels on various transcripts.

RNA Decapping as a Critical Survival Mechanism

The CRISPRi screen identified 1,293 genes that modulate decitabine response. Notably, genes involved in RNA decapping, such as DCP2 and DCPS, emerged as essential for cell survival during decitabine treatment. These enzymes typically function as a quality control system for mRNA. When decitabine induces aberrant or "junk" transcripts, the cell becomes heavily dependent on these decapping enzymes to clear the transcriptomic noise. Inhibiting this process using the compound RG3039 showed potent synergy with decitabine, leading to increased apoptosis and cell cycle arrest across multiple AML models.

Destabilization of Pro-Survival Factors

The study further demonstrated that decitabine-induced $m^6A$ hypermethylation specifically targets the pro-survival transcript BCL2 for degradation. This finding provides a robust mechanistic rationale for the clinical success of combining decitabine with BCL2 inhibitors like venetoclax. Additionally, the loss of the tumor suppressor PTEN was found to significantly sensitize cells to decitabine, suggesting PTEN status as a potential biomarker for patient selection.

Stability Over Translation

Interestingly, while decitabine profoundly impacts RNA stability and abundance, Ribo-seq data indicated minimal changes in translation efficiency. This suggests that the drug's primary impact on the RNA layer is mediated through decay pathways rather than the modulation of protein synthesis rates.

Conclusion

This study shifts the paradigm of decitabine research from a purely DNA-centric view to one that encompasses complex RNA dynamics. By revealing that RNA decapping and $m^6A$-mediated decay are central to the drug's efficacy, the research identifies new opportunities for combination therapies, particularly the use of DCPS inhibitors. While the metabolic flux of the SAM pool requires further direct validation, these findings provide a comprehensive map of the molecular vulnerabilities induced by DNA hypomethylation in leukemia.

Summary updated

Abstract

SUMMARY The search for new approaches in cancer therapy requires a mechanistic understanding of cancer vulnerabilities and anti-cancer drug mechanisms of action. Problematically, some effective therapeutics target cancer vulnerabilities that have poorly defined mechanisms of anti-cancer activity. One such drug is decitabine, a frontline therapeutic approved for the treatment of high-risk acute myeloid leukemia (AML). Decitabine is thought to kill cancer cells selectively via inhibition of DNA methyltransferase enzymes, but the genes and mechanisms involved remain unclear. Here, we apply an integrated multiomics and CRISPR functional genomics approach to identify genes and processes associated with response to decitabine in AML cells. Our integrated multiomics approach reveals RNA dynamics are key regulators of DNA hypomethylation induced cell death. Specifically, regulation of RNA decapping, splicing and RNA methylation emerge as important regulators of cellular response to decitabine.
BibTeX
@misc{ge2022multiomics,
  author = {Alex Y. Ge and Abolfazl Arab and Raymond Dai and Albertas Navickas and Lisa Fish and Kristle Garcia and Hosseinali Asgharian and Jackson Goudreau and Sean M. Lee and Kathryn Keenan and Melissa B. Pappalardi and Michael T. McCabe and Laralynne Przybyla and Hani Goodarzi and Luke A. Gilbert},
  title = {{A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation}},
  year = {2022},
  doi = {10.1101/2022.12.14.518457},
  howpublished = {bioRxiv},
}
Figure